Prelude Therapeutics (PRLD) Shares Outstanding (Weighted Average) (2019 - 2026)

Prelude Therapeutics has disclosed Shares Outstanding (Weighted Average) across 8 years of filings, most recently posting $82.5 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $82.5 million, up 8.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $82.5 million (up 8.6% YoY), and the FY2025 annual result was $19.5 million, down 74.23% from the prior year.
• Shares Outstanding (Weighted Average) came in at $82.5 million for Q1 2026 at Prelude Therapeutics, up from $19.5 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $82.5 million in Q1 2026 to a low of $19.5 million in Q4 2025.
• The 5-year median for Shares Outstanding (Weighted Average) is $67.6 million (2023), against an average of $61.8 million.
• Across the five-year window, Shares Outstanding (Weighted Average) jumped 58.65% in 2024 and slumped 74.23% in 2025, its largest moves.
• Prelude Therapeutics' Shares Outstanding (Weighted Average) stood at $47.4 million in 2022, then grew by 27.41% to $60.4 million in 2023, then advanced by 25.6% to $75.8 million in 2024, then plunged by 74.23% to $19.5 million in 2025, then surged by 322.48% to $82.5 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $82.5 million (Q1 2026), $19.5 million (Q4 2025), and $76.0 million (Q3 2025), per Business Quant data.